The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

M.G. Dal Bello,Rosangela Filiberti,Angela Alama,Anna Maria Orengo,Michele Mussap,Simona Coco,Irene Vanni,Simona Boccardo,E. Rijavec,C. Genova,F. Biello,G. Barletta,Giovanni Rossi,Marco Tagliamento,Claudia Maggioni,Francesco Grossi

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

2019

M.G. Dal Bello
Rosangela Filiberti
Angela Alama
Anna Maria Orengo
Michele Mussap
Simona Coco
Irene Vanni
Simona Boccardo
E. Rijavec
C. Genova
F. Biello
G. Barletta
Giovanni Rossi
Marco Tagliamento
Claudia Maggioni
Francesco Grossi

Background CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively. Their role in cancer immunotherapy needs to be elucidated.

Keywords:

Carcinoma
non-small cell lung cancer (NSCLC)
Oncology
Nivolumab
Immunology
Cancer immunotherapy
Internal medicine
Cell
Adenocarcinoma
Lung cancer
Chemotherapy
Medicine
Immunotherapy
Diabetes mellitus
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations